Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook

Core Insights - Eli Lilly and Company is recognized as a strong investment opportunity, particularly with the launch of its weight-loss drug Zepbound, which will be available for self-pay at $299 per month for the 2.5 mg dose [1] Group 1: Product Launch and Pricing - Zepbound, a once-weekly injectable for adults with obesity or overweight-related conditions, will be available for self-pay starting at $299 per month [1][2] - A new savings card will allow eligible adults with a valid prescription to access the same pricing nationwide, although it is limited to the KwikPen format [2] Group 2: Access and Cost Reduction Initiatives - Eli Lilly received a boost from new Medicare and Medicaid services implementation details aimed at enhancing access to medications at lower costs [3] - With the new Medicare and Medicaid Services details, Zepbound and other medications will be available through Medicare Part D plans, capping out-of-pocket costs for beneficiaries at $50 a month, with cost-sharing limited to $245 a month before reaching the deductible [4] Group 3: Company Overview - Eli Lilly is a global pharmaceutical leader focused on developing medicines for diabetes, obesity, cancer, and immunological disorders, with notable products including Mounjaro and Zepbound [5]